Leaflet BORTEZOMIB ACTAVIS 3.5mg powder for injection
Indicated for: multiple myeloma
Route of administration: injectable
Substance: bortezomib (proteasome inhibitor)
ATC: L01XG01 (Antineoplastic and immunomodulating agents | Other antineoplastic agents | Proteasome inhibitors)
This medicine may affect fertility.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
This medicine may affect the nerves or nervous system.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Bortezomib is a medication used for the treatment of multiple myeloma and mantle cell lymphoma. It is a proteasome inhibitor that interferes with essential cellular processes in cancer cells, leading to their death.
The medication is administered via subcutaneous or intravenous injection, usually in treatment cycles, as directed by a doctor. The dosage and duration of treatment are adjusted based on the patient's condition and response to therapy.
Common side effects include fatigue, nausea, diarrhea, peripheral neuropathy, and decreased blood cell counts. In rare cases, more severe adverse effects such as heart failure or pulmonary toxicity may occur.
Bortezomib is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
General data about BORTEZOMIB ACTAVIS 3.5mg
- Substance: bortezomib
- Date of last drug list: 01-08-2025
- Commercial code: W61990001
- Concentration: 3.5mg
- Pharmaceutical form: powder for injection
- Quantity: 1
- Product type: generic
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for bortezomib
Concentrations available for bortezomib
- 1mg
- 2.5mg
- 2.5mg/ml
- 25mg/ml
- 3.5mg